Teva Pharmaceutical Industries (TEVA) Stock Price, News & Info | The Motley Fool
Teva shares approach 20-year low amid Moody's warning and other woes | Fierce Pharma
Teva Seeks New CFO as It Faces High Debt Levels, Opioid Litigation - WSJ
Teva Reports Fourth Quarter and Full Year 2022 Financial Results | Business Wire
Teva (TEVA) to Report Q1 Earnings: What's in the Cards? | Nasdaq
Teva Reports Third Quarter 2022 Financial Results
Teva exits Massachusetts as Cambridge site falls victim to restructuring - Boston Business Journal
Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
Teva expects to start paying U.S. opioid settlement in 2023 | Reuters
Teva's stock performance. (Source: Teva Pharmaceutical Industries... | Download Scientific Diagram
Teva Stock: Teva Guides To Its First Year Of Growth Since 2017, But There's A Caveat | Investor's Business Daily
DEF 14A
Teva Pharmaceuticals Q4 2016 Earnings
IP finance: When a company's future is caught in the generic drug/proprietary drug crosshairs
TEVA -- Is Its Stock Price A Worthy Investment? Learn More.
Teva Reports Third Quarter 2020 Financial Results | Business Wire
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment? - Simply Wall St News
Teva Pharmaceutical Industries (TEVA) Analysts Prediction, Stock Forecast & Price Targets - Simply Wall St
Teva | Partnership | Direct Relief
Teva reaches opioid settlement, Credit Suisse names new CEO, Twitter to hold shareholder vote
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare Finance News
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva timeline: CEO says 20-25 manufacturing plants to close in next two years
Teva reaches opioid settlement, Credit Suisse names new CEO, Twitter to hold shareholder vote - YouTube
Teva's Copaxone Successors Are Still Far From Success | Ctech
